Publications

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

Authors: J Remon, C Caramella, C Jovelet, L Lacroix, A Lawson, S Smalley, K Howarth,...

Research group:

E-pub date: 1 Apr 2017

Journal name: Ann Oncol

Evaluation of illumination system uniformity for wide-field biomedical hyperspectral imaging

Authors: TW Sawyer, AS Luthman, SE Bohndiek

Research group: Bohndiek Group

E-pub date: 1 Apr 2017

Journal name: Journal of Optics

Aging increases cell-to-cell transcriptional variability upon immune stimulation.

Authors: CP Martinez-Jimenez, N Eling, H-C Chen, CA Vallejos, AA Kolodziejczyk, F Co...

Research group: de la Roche Group

E-pub date: 31 Mar 2017

Journal name: Science

Cell cycle-coupled expansion of AR activity promotes cancer progression.

Authors: C McNair, A Urbanucci, CES Comstock, MA Augello, JF Goodwin, R Launchbury, ...

Research group: Carroll Group

E-pub date: 23 Mar 2017

Journal name: Oncogene

The evolutionary and phylogeographic history of woolly mammoths: a comprehensive mitogenomic analysis.

Authors: D Chang, M Knapp, J Enk, S Lippold, M Kircher, A Lister, RDE MacPhee, C Wid...

Research group: Hannon Group

E-pub date: 22 Mar 2017

Journal name: Sci Rep

TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer.

Authors: R Fagerholm, S Khan, MK Schmidt, M García-Closas, P Heikkilä, J Saarela, ...

Research group: Ali Group

E-pub date: 14 Mar 2017

Journal name: Oncotarget

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.

Authors: D Öhlund, A Handly-Santana, G Biffi, E Elyada, AS Almeida, M Ponz-Sarvise,...

Research group: Biffi Group

E-pub date: 6 Mar 2017

Journal name: J Exp Med

Corrigendum to “Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity” [Mol. Cell Endocrinol. 440 (2016) 138-150].

Authors: AW Nelson, AJ Groen, JL Miller, AY Warren, KA Holmes, GA Tarulli, WD Tilley...

Research group: Carroll Group

E-pub date: 5 Mar 2017

Journal name: Mol Cell Endocrinol

Filters

Research Groups

Core Facilities

Start date

End date

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

Evaluation of illumination system uniformity for wide-field biomedical hyperspectral imaging

Aging increases cell-to-cell transcriptional variability upon immune stimulation.

Cell cycle-coupled expansion of AR activity promotes cancer progression.

The evolutionary and phylogeographic history of woolly mammoths: a comprehensive mitogenomic analysis.

TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer.

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.

Corrigendum to “Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity” [Mol. Cell Endocrinol. 440 (2016) 138-150].

Themes

Filters

Research Groups

Core Facilities

Start date

End date

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

Evaluation of illumination system uniformity for wide-field biomedical hyperspectral imaging

Aging increases cell-to-cell transcriptional variability upon immune stimulation.

Cell cycle-coupled expansion of AR activity promotes cancer progression.

The evolutionary and phylogeographic history of woolly mammoths: a comprehensive mitogenomic analysis.

TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer.

Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.

Corrigendum to “Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity” [Mol. Cell Endocrinol. 440 (2016) 138-150].